News

Sep

1

2020 |

Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial

Jul

30

2020 |

Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes

Jul

15

2020 |

Update on Merck's New Scientific Efforts to Help Combat COVID-19

Jun

16

2020 |

Bayer Extends Clinical Development Program for Finerenone with Phase III Study in Patients with Heart Failure and Preserved Ejection Fraction

May

11

2020 |

MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy